On July 24, 2020, the U.S. FDA announced accelerated approval of the CAR-T cell therapy Brexucabtagene Autoleucel (Tecartus) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Lymphoma
On May 30, 2024, Bristol Myers Squibb (BMS) announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel, liso-cel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
On August 24, 2021, Novartis announced that in the BELINDA Phase III clinical trial, the use of Kymriah (CTL019, tisagenlecleucel) as a second-line treatment for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) failed to meet the primary endpoint of event-free survival (EFS) compared to standard of care (SOC).
🎗️ **Participants in China’s CAR-T ‘Lymphoma Value-Based Payment Plan’ have achieved complete remission.** 🎗️ Exciting news! Fosun Kite has just announced that the first participants in China’s “Lymphoma Value-Based Payment Plan” have achieved complete remission. These four patients, hailing from Shanghai, Guangzhou, and Hangzhou, have all reached complete remission after undergoing the innovative CAR-T cell Read More
In the case of axicabtagene ciloleucel, the T-cells are engineered to target and eliminate cells that express a protein called CD19, which is found on the surface of B-cells, including the cancerous B-cells in follicular lymphoma.
On December 21, 2023, Kite, a Gilead company, announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel), incorporating the pivotal Phase 3 ZUMA-7 study’s overall survival (OS) analysis.
On March 5, 2021, the U.S. Food and Drug Administration (FDA) approved Axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
On September 28, 2022, the European Commission (EC) approved the CD19 CAR-T cell therapy Yescarta (axicabtagene ciloleucel) for a new indication: the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) after one line of systemic therapy.